OXP elicits immunogenic cell death in several rodent models of colon cancer, and this effect determines its therapeutic efficacy in CRC patients [17]. In CRC patients, it has also been validated that 5-FU can increase the expression of PD-L1 on CRC cells and improve the response rate with ICI intervention [33, 34]. Here, CD274 is linked to colonic neoplasm.